Drug intelligence / Profile preview

IBIO-301

Development stage: Unknown
Lead developer: Immune Biosolutions
Modality: Antibody-Based Therapeutics

Overview

IBIO-301 is an investigational antibody drug developed by Immune Biosolutions. It acts as a dual inhibitor of Leukocyte immunoglobulin-like receptor B1 (LILRB1) and Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2). These receptors are immune checkpoint molecules expressed on various immune cells, and their inhibition is being explored as a novel approach in cancer immunotherapy. The primary therapeutic area for IBIO-301 is neoplasms (cancers), but the drug remains at the discovery stage of development[1][4].

Targets

LILRB1 (Leukocyte immunoglobulin-like receptor subfamily B member 1)LILRB2 (Leukocyte immunoglobulin-like receptor subfamily B member 2)

Beyond the preview

Go deeper on IBIO-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBIO-301.

Explore the full profile